Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain
Apellis Pharmaceuticals still can’t pinpoint exactly what’s behind the rare cases of eye inflammation that’s been reported in patients taking its geographic atrophy drug Syfovre. And despite execs’ pledge to be transparent, the lack of answers is scaring investors.
Both the American Society of Retina Specialists’ Research and Safety in Therapeutics Committee (ASRS ReST committee) — which first flagged the safety concerns — and Apellis issued updates over the weekend on their respective reviews, with slight discrepancies. The ASRS ReST committee confirmed the discovery of two more cases of retinal vasculitis in the past two weeks, bringing the total number of cases to eight; meanwhile, by Apellis’ count, there have been seven confirmed cases of occlusive/non-occlusive retinal vasculitis since Syfovre’s launch in March.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.